168 related articles for article (PubMed ID: 30174764)
1. Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.
Lee JH; Yu SE; Kim KH; Yu MH; Jeong IH; Cho JY; Park SJ; Lee WJ; Han SS; Kim TH; Hong EK; Woo SM; Yoo BC
EPMA J; 2018 Sep; 9(3):287-297. PubMed ID: 30174764
[TBL] [Abstract][Full Text] [Related]
2. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
[TBL] [Abstract][Full Text] [Related]
3. Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.
Lee JH; Yoo BC; Kim YH; Ahn SA; Yeo SG; Cho JY; Kim KH; Kim SC
BioData Min; 2016; 9():32. PubMed ID: 27752286
[TBL] [Abstract][Full Text] [Related]
4. Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer.
Kim SC; Kim MK; Kim YH; Ahn SA; Kim KH; Kim K; Kim WK; Lee JH; Cho JY; Yoo BC
Oncol Lett; 2014 Aug; 8(2):566-574. PubMed ID: 25013471
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry.
Zalevskaja K; Mecklin JP; Seppälä TT
Front Oncol; 2023; 13():1123901. PubMed ID: 36816932
[TBL] [Abstract][Full Text] [Related]
6. Serum Metabolomic Profiles for Human Pancreatic Cancer Discrimination.
Itoi T; Sugimoto M; Umeda J; Sofuni A; Tsuchiya T; Tsuji S; Tanaka R; Tonozuka R; Honjo M; Moriyasu F; Kasuya K; Nagakawa Y; Abe Y; Takano K; Kawachi S; Shimazu M; Soga T; Tomita M; Sunamura M
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28375170
[TBL] [Abstract][Full Text] [Related]
7. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates.
Minicozzi P; Cassetti T; Vener C; Sant M
Cancer Epidemiol; 2018 Aug; 55():52-60. PubMed ID: 29777994
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of quantitative analysis of microRNA in bile samples obtained during endoscopic retrograde cholangiopancreatography for malignant biliary strictures.
Kuniyoshi N; Imazu H; Masuzaki R; Yamazaki M; Hamana S; Nomura S; Hayama J; Osawa R; Yamada K; Fujisawa M; Saito K; Kogure H
PLoS One; 2023; 18(8):e0289537. PubMed ID: 37561751
[TBL] [Abstract][Full Text] [Related]
9. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
Umemoto K; Yamamoto H; Oikawa R; Takeda H; Doi A; Horie Y; Arai H; Ogura T; Mizukami T; Izawa N; Moore JA; Sokol ES; Sunakawa Y
J Natl Cancer Inst; 2022 Sep; 114(9):1279-1286. PubMed ID: 35583261
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
Oncologist; 2012; 17(1):13. PubMed ID: 22210086
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.
Sandanayake NS; Camuzeaux S; Sinclair J; Blyuss O; Andreola F; Chapman MH; Webster GJ; Smith RC; Timms JF; Pereira SP
BMC Clin Pathol; 2014 Feb; 14(1):7. PubMed ID: 24495412
[TBL] [Abstract][Full Text] [Related]
12. Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer.
Høgdall D; O'Rourke CJ; Larsen FO; Zarforoushan S; Christensen TD; Ghazal A; Boisen MK; Muñoz-Garrido P; Johansen JS; Andersen JB
J Hepatol; 2022 Oct; 77(4):1047-1058. PubMed ID: 35750139
[TBL] [Abstract][Full Text] [Related]
13. Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review.
Tominaga H; Matsuzaki J; Oikawa C; Toyoshima K; Manabe H; Ozawa E; Shimamura A; Yokoyama R; Serizawa Y; Ochiya T; Saito Y
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439378
[TBL] [Abstract][Full Text] [Related]
14. Functional metabolome profiling may improve individual outcomes in colorectal cancer management implementing concepts of predictive, preventive, and personalized medical approach.
Yuan Y; Yang C; Wang Y; Sun M; Bi C; Sun S; Sun G; Hao J; Li L; Shan C; Zhang S; Li Y
EPMA J; 2022 Mar; 13(1):39-55. PubMed ID: 35273658
[TBL] [Abstract][Full Text] [Related]
15. Low-mass-ion discriminant equation: a new concept for colorectal cancer screening.
Lee JH; Kim KH; Park JW; Chang HJ; Kim BC; Kim SY; Kim KG; Lee ES; Kim DY; Oh JH; Yoo BC; Kim IH
Int J Cancer; 2014 Apr; 134(8):1844-53. PubMed ID: 24096867
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.
Kikkawa S; Sogawa K; Satoh M; Umemura H; Kodera Y; Matsushita K; Tomonaga T; Miyazaki M; Yokosuka O; Nomura F
Int J Proteomics; 2012; 2012():108609. PubMed ID: 22888427
[TBL] [Abstract][Full Text] [Related]
17. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
[TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
20. Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer.
Kishimoto T; Eguchi H; Nagano H; Kobayashi S; Akita H; Hama N; Wada H; Kawamoto K; Tomokuni A; Tomimaru Y; Umeshita K; Doki Y; Mori M
Cancer Sci; 2013 Dec; 104(12):1626-31. PubMed ID: 24118467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
